Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a leading clinical-stage biopharmaceutical company headquartered in the United States, dedicated to the discovery and development of engineered monoclonal antibody and protein therapeutics. The primary goal of Xencor is to address severe and life-threatening diseases that currently have unmet medical needs, such as autoimmune diseases, asthma, and various forms of cancer.
Xencor leverages its proprietary XmAb® technology platform to enhance the natural immune functions of antibodies while maintaining a high degree of similarity to natural antibodies (over 99.5% identity). This innovative approach allows Xencor to create biotherapeutics that are more potent, safer, and longer-lasting, thereby improving patient outcomes and quality of life.
One of the key strengths of Xencor's XmAb technology is its ability to dramatically augment the immune functions of antibodies. This has resulted in a robust pipeline of product candidates, including eight in human clinical trials. Notable candidates in clinical development include XmAb5871 and XmAb7195, with several others such as XmAb14045 and XmAb662 in the pre-clinical stage. These candidates are being developed both by Xencor and in collaboration with pharmaceutical partners.
Financially, Xencor generates revenue through research and development collaborations and the licensing of its internally developed drug candidates. This collaborative approach not only advances their pipeline but also brings in essential funding to support ongoing and future projects.
Recently, Xencor has made significant strides in expanding its partnerships and advancing its clinical trials. These developments are crucial as they bring the company closer to delivering breakthrough treatments that can transform patient care in various therapeutic areas.
Overall, Xencor, Inc. stands out in the biopharmaceutical industry for its innovative approach to antibody and protein engineering, with a mission to fundamentally improve the treatment of serious diseases and enhance the quality of life for patients around the world.
Xencor, Inc. (NASDAQ:XNCR) announced the appointment of Dr. Nancy Valente to its board of directors, bringing over 20 years of experience in late-stage biopharmaceutical development, particularly in oncology. Dr. Valente previously held a senior position at Genentech, where she played a critical role in the launch of several therapies. Concurrently, Yujiro S. Hata, a director since 2015, resigned from the board. The leadership change is expected to enhance Xencor's strategic direction as it continues developing engineered antibodies for cancer and autoimmune diseases.
Xencor, Inc. reported its financial results for Q2 2022, with total revenue of $30.2 million, down from $67.4 million in Q2 2021. The company recognized $22.1 million in royalties from Vir Biotechnology and $6.7 million from Alexion Pharmaceuticals. R&D expenses declined to $47.1 million from $49.5 million year-over-year, while G&A expenses increased to $11.1 million. Xencor posted a net loss of $34 million, or $(0.57) per share, compared to a net income of $52.2 million, or $0.87 per share, in Q2 2021. The company anticipates having sufficient cash to fund operations through 2025.
On August 2, 2022, Caris Life Sciences and Xencor, Inc. (NASDAQ: XNCR) announced a strategic agreement to develop XmAb® bispecific antibodies targeting novel cancer treatment options. Caris will utilize its proprietary discovery platform to identify these targets, while Xencor will leverage its XmAb engineering technology. Xencor will receive exclusive options to commercialize products related to three targets, alongside a payment of up to $120 million in milestones and royalties. This collaboration aims to address the need for new therapeutic targets in oncology.
Xencor, Inc. (NASDAQ: XNCR) will announce its second quarter 2022 financial results post-market on August 3, 2022. A conference call and webcast will take place at 4:30 p.m. ET to discuss these results alongside a corporate update. The webcast will be accessible on the company's investor website and available for archiving for 30 days.
Xencor specializes in developing engineered antibodies and cytokines aimed at treating cancer and autoimmune disorders, with over 20 candidates in clinical development using its advanced XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) recently announced initial data from the Phase 1 clinical study of XmAb104, a bispecific antibody targeting PD-1 and ICOS, in patients with advanced solid tumors. Results will be presented at the ASCO Annual Meeting on June 5, 2022. The study aims to assess safety and tolerability while determining the maximum tolerated dose (MTD). With 62 patients treated, XmAb104 showed a distinct safety profile, and two confirmed partial responses were observed. The recommended dose for further study is 10 mg/kg, suggesting promising therapeutic potential.
Xencor, a clinical-stage biopharmaceutical company, reported strong Q1 2022 results, highlighting revenues of $85.5 million, up from $34 million in Q1 2021. The company has a robust financial position with $683.6 million in cash and marketable securities. Key developments include dosing the first patient in a Phase 2 trial for plamotamab. However, Xencor foresees a decline in future royalty revenues from sotrovimab. Overall, the company is advancing multiple clinical programs while maintaining a net income of $23.6 million or $0.39 per diluted share.
Xencor, Inc. (NASDAQ: XNCR), a biopharmaceutical company focused on engineered antibodies and cytokines, will release its first quarter 2022 financial results on May 5, 2022, after market close. A conference call and webcast will be held that same day at 4:30 p.m. ET to discuss the results and provide corporate updates. The event can be accessed via phone or through the company’s website. Currently, more than 20 candidates utilizing Xencor’s XmAb® technology are in clinical development, with three marketed by partners.
Xencor, Inc. (NASDAQ: XNCR) has presented new data on its preclinical-stage IL-18 and LAG3-targeted IL-15 cytokine programs at the AACR Annual Meeting 2022. The company introduced a decoy-resistant IL18-Fc fusion protein and a LAG-3 targeted IL15/IL15Rα-Fc fusion protein aimed at preferential TIL expansion. Xencor plans to submit an investigational new drug application for XmAb662 later this year, a promising IL12-Fc cytokine with observed anti-tumor activity. These developments aim to enhance cytokine therapeutics' efficacy while reducing systemic toxicity.
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, announced it will present preclinical data on two new XmAb® cytokine programs at the AACR Annual Meeting in New Orleans from April 8-13, 2022. The data includes a decoy-resistant IL18-Fc fusion protein and a LAG-3 targeted IL15/IL15α-Fc fusion protein. The presentations are scheduled for April 11 and April 12, highlighting their innovative approaches to enhance immune responses in cancer treatment. Xencor's XmAb technology enables the creation of long-acting therapeutic candidates for improved patient outcomes.
Xencor, a clinical-stage biopharmaceutical company, reported its financial results for Q4 and FY 2021, highlighting significant advancements in its drug portfolio. The company initiated Phase 2 trials for vudalimab in prostate cancer and established a collaboration with Janssen. Revenues surged to $154 million in Q4, compared to $42 million in Q4 2020, while full-year revenues reached $275 million, up from $123 million. Net income for 2021 was $82.6 million, a turnaround from a net loss of $69.3 million in 2020. Xencor expects to maintain cash reserves of $500-$550 million by the end of 2022.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
What is Xencor, Inc.?
What is the XmAb technology?
What are some key products in Xencor's pipeline?
How does Xencor generate revenue?
Where is Xencor, Inc. based?
What diseases does Xencor target?
What makes Xencor's biotherapeutics unique?
Who are Xencor's partners?
What recent achievements has Xencor made?
What is the primary goal of Xencor?
